Cargando…

Efficacy and safety comparison between liraglutide as add-on therapy to insulin and insulin dose-increase in Chinese subjects with poorly controlled type 2 diabetes and abdominal obesity

OBJECTIVE: To assess the efficacy and safety of adding liraglutide to established insulin therapy in poorly controlled Chinese subjects with type 2 diabetes and abdominal obesity compared with increasing insulin dose. METHODS: A 12-week, randomized, parallel-group study was carried out. A total of 8...

Descripción completa

Detalles Bibliográficos
Autores principales:	Li, Chun-jun, Li, Jing, Zhang, Qiu-mei, Lv, Lin, Chen, Rui, Lv, Chun-feng, Yu, Pei, Yu, De-min
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2012
Materias:	Original Investigation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3533748/ https://www.ncbi.nlm.nih.gov/pubmed/23153177 http://dx.doi.org/10.1186/1475-2840-11-142

Ejemplares similares

Preserved pharmacokinetics and pharmacodynamics of insulin degludec and liraglutide when administered as insulin degludec/liraglutide in a Chinese population
por: Liu, Hongzhong, et al.
Publicado: (2021)

Changes in liraglutide-induced body composition are related to modifications in plasma cardiac natriuretic peptides levels in obese type 2 diabetic patients
por: Li, Chun-Jun, et al.
Publicado: (2014)

Liraglutide treatment improves the coronary microcirculation in insulin resistant Zucker obese rats on a high salt diet
por: Sukumaran, Vijayakumar, et al.
Publicado: (2020)

Cost-effectiveness of liraglutide versus lixisenatide as add-on therapies to basal insulin in type 2 diabetes
por: Ericsson, Åsa, et al.
Publicado: (2018)

Insulin resistance in Chinese patients with type 2 diabetes is associated with C-reactive protein independent of abdominal obesity
por: Lu, Bin, et al.
Publicado: (2010)

Pharmacokinetic Properties of Liraglutide as Adjunct to Insulin in Subjects with Type 1 Diabetes Mellitus
por: Mader, Julia K., et al.
Publicado: (2016)

Managing insulin resistance: role of liraglutide
por: Kalra, Sanjay, et al.
Publicado: (2010)

Metformin add-on continuous subcutaneous insulin infusion on precise insulin doses in patients with type 2 diabetes
por: Li, Feng-fei, et al.
Publicado: (2018)

Carotid Intima-media thickness in childhood and adolescent obesity relations to abdominal obesity, high triglyceride level and insulin resistance
por: Fang, Jie, et al.
Publicado: (2010)

Pharmacometabolomic profiles in type 2 diabetic subjects treated with liraglutide or glimepiride
por: Jendle, J., et al.
Publicado: (2021)

Zinc-α(2)-Glycoprotein Is Associated With Insulin Resistance in Humans and Is Regulated by Hyperglycemia, Hyperinsulinemia, or Liraglutide Administration: Cross-sectional and interventional studies in normal subjects, insulin-resistant subjects, and subjects with newly diagnosed diabetes
por: Yang, Mengliu, et al.
Publicado: (2013)

Lixisenatide as add-on therapy to basal insulin
por: Brown, Dominique Xavier, et al.
Publicado: (2013)

Hyperinsulinemia improves ischemic LV function in insulin resistant subjects
por: Heck, Patrick M, et al.
Publicado: (2010)

Severe Abdominal Lipohypertrophy Due to Poor Insulin Management
por: Lee, Sang Ho, et al.
Publicado: (2022)

Hepatic adenylate cyclase 3 is upregulated by Liraglutide and subsequently plays a protective role in insulin resistance and obesity
por: Liang, Y, et al.
Publicado: (2016)

Impact of insulin resistance on subclinical left ventricular dysfunction in normal weight and overweight/obese japanese subjects in a general community
por: Hirose, Kazutoshi, et al.
Publicado: (2021)

Comparison between liraglutide alone and liraglutide in combination with insulin on osteoporotic rats and their effect on bone mineral density
por: Chen, Kai, et al.
Publicado: (2021)

Liraglutide as Add-On Therapy to Insulin in Type 2 Diabetes Mellitus: A Retrospective, Observational Study From a Daily Clinical Practice Setting in Switzerland
por: Lipowsky, Christof, et al.
Publicado: (2015)

Liraglutide Improves Cardiovascular Risk as an Add-on to Metformin and Not to Insulin Secretagogues in Type 2 Diabetic Patients: A Real-life 48-Month Retrospective Study
por: Ciresi, Alessandro, et al.
Publicado: (2017)

Cardiovascular outcomes and healthcare costs of liraglutide versus basal insulin for type 2 diabetes patients at high cardiovascular risk
por: Huang, Wan-Chun, et al.
Publicado: (2021)

Successful control of a case of severe insulin allergy with liraglutide
por: Kawanami, Daiji, et al.
Publicado: (2013)

DUAL II China: Superior HbA1c reductions and weight loss with insulin degludec/liraglutide (IDegLira) versus insulin degludec in a randomized trial of Chinese people with type 2 diabetes inadequately controlled on basal insulin
por: Pei, Yu, et al.
Publicado: (2021)

Insight into Insulin Secretion from Transcriptome and Genetic Analysis of Insulin-Producing Cells of Drosophila
por: Cao, Jian, et al.
Publicado: (2014)

Early impairment of contractility reserve in patients with insulin resistance in comparison with healthy subjects
por: Cadeddu, Christian, et al.
Publicado: (2013)

The use of metformin as an add-on therapy to insulin in the treatment of poorly controlled type 1 diabetes mellitus in adolescents
por: Sikorskaya, Katsiaryna, et al.
Publicado: (2021)

Insulin degludec/liraglutide (IDegLira) maintains glycaemic control and improves clinical outcomes, regardless of pre‐trial insulin dose, in people with type 2 diabetes that is uncontrolled on basal insulin
por: Meneghini, L., et al.
Publicado: (2019)

Jejunal Insulin Signalling Is Increased in Morbidly Obese Subjects with High Insulin Resistance and Is Regulated by Insulin and Leptin
por: Gutierrez-Repiso, Carolina, et al.
Publicado: (2020)

Liraglutide Increases FGF-21 Activity and Insulin Sensitivity in High Fat Diet and Adiponectin Knockdown Induced Insulin Resistance
por: Yang, Mengliu, et al.
Publicado: (2012)

Multiorgan Insulin Sensitivity in Lean and Obese Subjects
por: Conte, Caterina, et al.
Publicado: (2012)

Bromocriptine and insulin sensitivity in lean and obese subjects
por: Bahler, L, et al.
Publicado: (2016)

Role of adiponectin and free fatty acids on the association between abdominal visceral fat and insulin resistance
por: Medina-Urrutia, Aida, et al.
Publicado: (2015)

Gender differences in factors influencing insulin resistance in elderly hyperlipemic non-diabetic subjects
por: Lichnovská, Radka, et al.
Publicado: (2002)

Superior efficacy of insulin degludec/liraglutide versus insulin glargine U100 as add‐on to sodium‐glucose co‐transporter‐2 inhibitor therapy: A randomized clinical trial in people with uncontrolled type 2 diabetes
por: Philis‐Tsimikas, Athena, et al.
Publicado: (2019)

Insulin degludec/liraglutide (IDegLira) for the treatment of type 2 diabetes
por: Gough, Stephen CL, et al.
Publicado: (2016)

Insulin and liraglutide attenuate brain pathology in diabetic mice by enhancing the Wnt/β-catenin signaling pathway
por: Zhao, Yuan, et al.
Publicado: (2022)

Stage-Specific Plasticity in Ovary Size Is Regulated by Insulin/Insulin-Like Growth Factor and Ecdysone Signaling in Drosophila
por: Mendes, Cláudia C., et al.
Publicado: (2016)

Aging Affects Insulin Resistance, Insulin Secretion, and Glucose Effectiveness in Subjects with Normal Blood Glucose and Body Weight
por: Huang, Li-Ying, et al.
Publicado: (2023)

Author Correction: Liraglutide Improves Cardiovascular Risk as an Add-on to Metformin and Not to Insulin Secretagogues in Type 2 Diabetic Patients: A Real-life 48-Month Retrospective Study
por: Ciresi, Alessandro, et al.
Publicado: (2018)

Association of serum fetuin-B with insulin resistance and pre-diabetes in young Chinese women: evidence from a cross-sectional study and effect of liraglutide
por: Xia, Xuyun, et al.
Publicado: (2021)

Sitagliptin is effective and safe as add-on to insulin in patients with absolute insulin deficiency: a case series
por: Kutoh, Eiji
Publicado: (2011)

Cannot write session to /tmp/vufind_sessions/sess_0ojodjn9rrv6ujf3c03dud9emk